Lice Treatment Market

The growing prevalence of lice infestation to boost the market growth

Lice are pathogens or parasites found on people's skulls and bodies, including their private parts. Humans are affected by three types of lice: body lice, head lice, and pubic lice. Head lice are a common, itchy, and highly contagious condition in kindergarten, daycare centers, and schools. Head lice infestations are common among children. Most infected people do not experience severe symptoms. Some people, however, have severe reactions to louse feeding. Perpetual itching of the scalp is a common sign of head lice infestation, and it can cause you to lose concentration at work, school, or while sleeping.

Excessive scratching can result in lymphadenopathies and secondary skin infections. As a result, such factors will drive up market CAGR for lice treatment solutions over the forecast period.

A larger plague pool and a growing child population are anticipated to provide growth opportunities for players in the  lice treatment market share. Lice, for example, are a common issue, particularly among children. Every year, millions of people get head lice. As per the American Academy of Dermatology, head-lice infestations are most common in schools. Every year, it is estimated that 6 to 12 million children aged 3 to 12 in the United States have head lice. This will likely increase the demand for safe and effective lice treatment in North America.

In the past, toxic insecticides were frequently used to treat head lice infestations. However, these treatments could have adverse effects on end users, including exposure to dangerous chemicals, allergic reactions, unintentional poisoning, etc. The increased prevalence of head lice infestations is directly related to the development of insecticide resistance brought on by the repeated usage of these chemical formulations. Only after a comprehensive, evidence-based evaluation of the formulations' safety and efficacy can manufacturers develop a new pediculicide that is neither detrimental to the consumer nor the environment.

Companies' investments in research and development to create safe head lice treatment formulas will boost the lice treatment market revenue.

Innovation in lice treatment products significantly influences the Global Lice Treatment Market Industry. The introduction of new formulations, such as natural and chemical-free options, caters to the growing consumer preference for safer alternatives. Companies are increasingly investing in research and development to create effective treatments that minimize side effects. For instance, products utilizing essential oils and botanical extracts are gaining traction among health-conscious consumers. This trend not only enhances product offerings but also attracts a broader customer base. As a result, the market is anticipated to grow at a CAGR of 7.28% from 2025 to 2035, reflecting the impact of innovation on market dynamics.

In the Global Lice Treatment Market Industry, increased awareness and education regarding lice prevention and treatment play a crucial role in driving market growth. Educational campaigns by health organizations and schools emphasize the importance of early detection and treatment of lice infestations. This heightened awareness encourages parents to seek out effective lice treatment products, thereby expanding the market. Furthermore, the availability of information through various channels, including social media and healthcare providers, contributes to informed decision-making. As a result, the market is expected to grow significantly, with projections indicating a rise to 0.25 USD Billion by 2035.

Regulatory support and guidelines from health authorities contribute to the growth of the Global Lice Treatment Market Industry. Governments and health organizations provide recommendations for effective lice management, which often includes the use of approved treatment products. This regulatory framework ensures that consumers have access to safe and effective solutions. Additionally, guidelines for schools and childcare facilities regarding lice management foster a proactive approach to addressing infestations. As these regulations become more stringent, manufacturers are encouraged to comply, leading to an increase in the availability of quality products in the market. This supportive environment is likely to enhance market growth in the coming years.

The Global Lice Treatment Market Industry is characterized by several key trends and growth projections. The market is expected to reach 0.11 USD Billion in 2024, with a projected increase to 0.25 USD Billion by 2035. This growth trajectory suggests a robust demand for lice treatment solutions, driven by factors such as rising infestation rates and increased consumer awareness. The anticipated CAGR of 7.28% from 2025 to 2035 further underscores the market's potential for expansion. These trends indicate a dynamic landscape, where innovation and consumer preferences will shape the future of lice treatment solutions.

The Global Lice Treatment Market Industry experiences a notable increase in demand due to the rising incidence of lice infestations, particularly among school-aged children. Reports indicate that approximately 6 to 12 million infestations occur annually in the United States alone, highlighting a persistent public health concern. This trend is likely to drive the market, as parents seek effective treatment options. The growing awareness of lice transmission in schools and communities further amplifies the need for effective lice treatment solutions. Consequently, the market is projected to reach 0.11 USD Billion in 2024, reflecting the urgent need for effective lice management.

The Global Lice Treatment Market Industry benefits from the increasing market penetration of over-the-counter (OTC) lice treatment products. The convenience and accessibility of these products allow consumers to address lice infestations promptly without the need for a prescription. Retailers are expanding their offerings, making a variety of OTC treatments readily available in pharmacies and online platforms. This trend not only meets consumer demand but also encourages self-treatment, which may lead to higher sales volumes. As a result, the market is poised for growth, with the potential for increased revenue generation as more consumers opt for OTC solutions.

By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North America Lice Treatment market is expected to grow at a significant CAGR during the study period, owing to increased awareness about head lice diagnosis and the availability of efficient products. The largest regional market share can be attributed primarily to the expansion of the infection pool and the population's increased proportion of children. Moreover, significant companies offering modern health solutions are expected to drive regional development during the forecast period. Furthermore, increased product approvals contribute to market growth.

For instance, in July 2020, the FDA of the United States granted permission for Xeglyze, a medication used to treat head lice in people six months of age and older. A clinical trial testing the medication's effectiveness in preventing head lice infestations led to the FDA's approval of the drug. According to the study, Xeglyze effectively riddled the scalps of live head lice in about 80% of patients.

Furthermore, the significant countries studied in the market report are the United States, Canada, France, the United Kingdom, Italy, Germany, Spain, India, Australia, Japan, China, South Korea, and Brazil.

Figure 3:  LICE TREATMENT MARKET SHARE BY REGION 2022 (%)

Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

The European lice treatment market is the second largest in the world. The primary drivers of the market's expansion are the rising level of awareness in the region and the presence of advanced medical and healthcare facilities with modern technology. However, Europe's vulnerable pediatric population is a substantial market driver for the lice treatment industry growth. Further, the German market of lice treatment held the largest market share, and the UK was the fastest-growing market in the European region.

The Asia-Pacific Lice Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032 due to rising lice contamination in the region. Lice contamination is as high as 17% in India and 75% throughout Asia. On the other hand, the region's growing medical facilities and the existence of key market players have fueled the overall development of the market of lice treatment. Moreover, China’s market of lice treatment held the largest market share, and the Indian market was the fastest-growing in Asia-Pacific.

The lice treatment industry is highly competitive. The industry players are concentrating on releasing safe and effective treatments due to the increased adoption of long-term lice management. Key market players are making R&D investments to enhance their product products and services, which will facilitate the growth of the lice treatment industry. In addition to other significant market developments, market players are releasing new products, signing distribution channel contracts, combining with other businesses, increasing expenditures, and collaborating with other organizations.

One of the primary business strategies manufacturers adopt in the lice treatment industry to benefit clients and expand the sector is manufacturing locally to reduce operating costs. In recent years, lice treatment industry has provided medicine with some of the most significant benefits. The lice treatment market major player such as Sanofi, Topaz Pharmaceuticals Inc, GlaxoSmithKline, Omega Pharma, Pfizer, Taro Pharmaceuticals, Arbor Pharmaceuticals, ICB PHARMA, Merck & Co. Inc and Galderma Laboratories L.P.

Kaken Pharmaceutical Co. Ltd (Kaken) is a specialized pharmaceutical company that conducts drug, agrochemical, and medical equipment research and development. Orthopedics, immunology, fungal infections, dermatology, inflammation, allergies, and pain relief are all services provided by the company. Kaken also sells fungicides, rice herbicides, chicken anticoccidials, and polypeptide antibiotics. The company researches inflammation, immunology, neuro pain relief, and fungal infection. It sells its products through license and distribution agreements with companies in the United States, Taiwan, Canada, China, Israel, South Korea, and Jordan, and it has sales offices throughout Japan.

Kaken Pharmaceuticals and Arbor Pharmaceuticals signed a licensing agreement in October 2019 to create and commercialize an anthelminthic agent, ivermectin lotion, 0.5% Sklice Lotion, in Japan for the hair lice treatment, a parasitic infectious disease.

The headquarters of the multinational British pharmaceutical and biotechnology business GSK plc, formerly known as GlaxoSmithKline plc, are located in London, England. SmithKline Beecham and Glaxo Wellcome merged to form this company in 2000. On the 2022 Fortune 500, GSK is rated #294 and is the tenth-largest pharmaceutical company, trailing only China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck. The business claimed in 2014 that it would make the first malaria vaccine, RTS,S, available for 5% more than the cost.

Several legacy GSK medicines, such as amoxicillin, are included in the World Health Organization's List of Essential Medicines.